Skip to Main Content

Author Details

Victor H Engelhard
University of Virginia School of Medicine
1976
198
74
PMIDPaper TitleJournal TitlePublished Year
36632563Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.Oncoimmunology2023
36189308Tumor necrosis factor receptor regulation of peripheral node addressin biosynthetic components in tumor endothelial cells.Front Immunol2022
35537413An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.Cancer Cell2022
36531040NK cells reduce anergic T cell development in early-stage tumors by promoting myeloid cell maturation.Front Oncol2022
34167064Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.Pathol Res Pract2021
33619119Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8<sup>+</sup> T Cells.Cancer Immunol Res2021
34454518Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163<sup>+</sup> myeloid cell infiltrates.J Transl Med2021
34597591B cells and cancer.Cancer Cell2021
34413086Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.Cancer Immunol Res2021
31472106Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice.J Invest Dermatol2020
33139300Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.Cancer Immunol Res2020
32385144MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.J Immunother Cancer2020
31134089The Antigen Processing and Presentation Machinery in Lymphatic Endothelial Cells.Front Immunol2019
31425296The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.Ann Surg2019
31057546Comparative Transcriptomic Analysis Identifies a Range of Immunologically Related Functional Elaborations of Lymph Node Associated Lymphatic and Blood Endothelial Cells.Front Immunol2019
31134297Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.Cancer Immunol Immunother2019
29311385Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.J Immunol2018
30141017Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.Methods Mol Biol2018
30288359Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.Oncoimmunology2018
29480817Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.J Clin Invest2018
27550523Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.J Proteome Res2017
29097419Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry.Cancer Immunol Res2017
28903331The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.Oncotarget2017
25968334Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity.Nat Commun2015
26216636Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.Adv Cancer Res2015
25857745Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.Nat Commun2015
24503860Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment.PLoS One2014
25580369Regulation of T-cell Tolerance by Lymphatic Endothelial Cells.J Clin Cell Immunol2014
25297629MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.Cancer Res2014
24935676Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.Pigment Cell Melanoma Res2014
23597565Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.Cancer Cell2013
24080233Regulatory T cells and vasectomy.J Reprod Immunol2013
24048523MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Sci Transl Med2013
23966998Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues.Front Immunol2013
23926324Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells.J Immunol2013
23060883Lymphatic endothelial cells - key players in regulation of tolerance and immunity.Front Immunol2012
22993390Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.Blood2012
20083666Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.J Immunol2010
20660615Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.J Exp Med2010
20212096CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors.J Immunol2010
20109752Targeting allergen to FcgammaRI reveals a novel T(H)2 regulatory pathway linked to thymic stromal lymphopoietin receptor.J Allergy Clin Immunol2010
20308365Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.J Exp Med2010
20417641Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.J Mol Biol2010
19234124Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.Proc Natl Acad Sci U S A2009
19581576Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.Proc Natl Acad Sci U S A2009
19342661N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.J Immunol2009
18086491Targeting Fel d 1 to FcgammaRI induces a novel variation of the T(H)2 response in subjects with cat allergy.J Allergy Clin Immunol2008
18836451Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.Nat Immunol2008
19017974MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.J Immunol2008
18641319Activated CD8 T cells redistribute to antigen-free lymph nodes and exhibit effector and memory characteristics.J Immunol2008
  • 1 - 50 of 198

Recommended Authors

University of Colorado Anschutz Medical Campus
Career Start Year 2002
Number of shared co-authors 0
The University of Texas at Austin
Career Start Year 2000
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 2
Duke University School of Medicine
Career Start Year 1992
Number of shared co-authors 0
University of Oklahoma Health Sciences Center
Career Start Year 1990
Number of shared co-authors 3
INSERM UMRS, University Paris Cite
Career Start Year 1990
Number of shared co-authors 0
Monash Biomedicine Discovery Institute, Monash University
Career Start Year 1989
Number of shared co-authors 2
Universidad Cardenal Herrera-CEU, CEU Universities
Career Start Year 1989
Number of shared co-authors 5
University of Perugia
Career Start Year 1988
Number of shared co-authors 1
Feinberg School of Medicine, Northwestern University
Career Start Year 1987
Number of shared co-authors 0
Translational Health Science and Technology Institute
Career Start Year 1987
Number of shared co-authors 0
Merck & Co. Inc.
Career Start Year 1987
Number of shared co-authors 1
University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 0
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Career Start Year 1982
Number of shared co-authors 5
Pathology Advanced Translational Research Unit, Emory University School of Medicine
Career Start Year 1981
Number of shared co-authors 4
St. Anna Children's Hospital, Medical University of Vienna
Career Start Year 1980
Number of shared co-authors 0
Vaccine and Gene Therapy Institute, Oregon Health & Science University
Career Start Year 1980
Number of shared co-authors 1
8Benaroya Research Institute
Career Start Year 1978
Number of shared co-authors 1
University of Pennsylvania Department of Pathology & Laboratory Medicine
Career Start Year 1978
Number of shared co-authors 4
Universite de Strasbourg
Career Start Year 1976
Number of shared co-authors 1
RIKEN BioResource Research Center
Career Start Year 1975
Number of shared co-authors 0
University of Copenhagen
Career Start Year 1974
Number of shared co-authors 5
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1971
Number of shared co-authors 4
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 1
RIKEN Center for Integrative Medical Sciences (IMS)
Career Start Year 1966
Number of shared co-authors 0
University of British Columbia
Career Start Year 1965
Number of shared co-authors 1
National Cancer Institute
Career Start Year 1963
Number of shared co-authors 1
University of Colorado School of Medicine
Career Start Year 1961
Number of shared co-authors 7
Ludwig Institute for Cancer Research
Career Start Year 1959
Number of shared co-authors 1

Collaborators

University of Virginia
Co-authored papers 49
University of Virginia
Co-authored papers 39
University of Virginia
Co-authored papers 34
Co-authored papers 9
University of Virginia School of Medicine.
Co-authored papers 8
Massachusetts Institute of Technology
Co-authored papers 8
University of Virginia School of Medicine
Co-authored papers 6
University of Washington
Co-authored papers 5
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
University of Virginia
Co-authored papers 5
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Co-authored papers 4
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
Co-authored papers 3
Co-authored papers 3
University of Virginia
Co-authored papers 3
National Cancer Institute, National Institutes of Health (NIH)
Co-authored papers 2
University of Virginia
Co-authored papers 2
University of Illinois at Chicago
Co-authored papers 2
Co-authored papers 2
University of Virginia
Co-authored papers 2
Agenus Inc.
Co-authored papers 2
University of Virginia School of Medicine
Co-authored papers 2
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Lewis-Sigler Institute for Integrative Genomics, Princeton University
Co-authored papers 1
Co-authored papers 1
Weill Cornell School of Medicine
Co-authored papers 1
University of Virginia, Emily Couric Clinical Cancer Center
Co-authored papers 1
Agenus Inc.
Co-authored papers 1